A nonprofit group focused on drug competition is attacking six key patents for Gilead Sciences Inc.’s blockbuster portfolio of hepatitis C drugs, telling the Patent Trial and Appeal Board that a crucial active ingredient was created using obvious scientific approaches.
The Initiative for Medicines, Access & Knowledge Inc. said Wednesday that it filed petitions for inter partes review at the PTAB in hopes of clearing the way sooner for generic versions of Gilead’s three hep C drugs: Sovaldi, Harvoni and Epclusa.